[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,59,88,123,151,181,209,236,262,302,328,349,379,403,436,467,491,514,535],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100580737","cardiovascular-function-and-response-to-stimulation-within-the-first-year-after-spinal-cord-injury-100580737",false,"NCT06841198","Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury","Assessing Cardiovascular Effects: Is There a Time Too Early for Spinal Stimulation in Acute SCI? A Year-Long Evaluation of Autonomic Function Following Injury","For the main study:\n\nInclusion Criteria:\n\n* Individuals with a spinal cord injury undergoing inpatient rehabilitation at the Kessler Institute for Rehabilitation\n* Between 18-75 years old\n* 7-50 days after injury\n* Injury level ≥ T6 (a cervical or a high-level chest injury)\n* Individuals experiencing low blood pressure after the injury\n* American Spinal Injury Association Impairment Scale (AIS) A or B\n\nExclusion Criteria:\n\n* A ventilator is needed for breathing.\n* Devices such as brain\u002Fspine\u002Fnerve stimulators, a cardiac pacemaker\u002Fdefibrillator, or intra-cardiac lines are present in the body.\n* There is a significant disease affecting the blood vessels or signals in the heart, or a recent heart attack (myocardial infarction) has occurred.\n* A new medication has been prescribed to treat blood pressure or a heart problem within the last five days (excluding midodrine).\n* There is a known infection in the body (e.g., urinary tract infection) or a current illness (e.g., recent diagnosis of deep vein thrombosis (DVT) or other blood clotting issues, and\u002For a pressure injury that might interfere with the study).\n* There is a history of seizures.\n* Pregnancy.\n\nFor the spin-off study ice-water vs ice-wrap test (see description in study arms):\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nInclusion:\n\nAge 18-75.\n\nInclusion for individuals with SCI:\n\n* Injury sustained more than 6 months ago\n* Injury level ≥ T6 (a cervical or a high-level chest injury)\n* American spinal injury association impairment scale (AIS) A - D\n\nExclusion:\n\nFoot lesions, uses a ventilator, devices such as brain\u002Fspine\u002Fnerve stimulators, significant or recent cardiovascular disease, known infection in the body",true,"ALL","18 Years","75 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to explore how cardiovascular function changes in the first year after a spinal cord injury, and to see how different treatments, like spinal stimulation through the skin (transcutaneous spinal stimulation), affect blood pressure.\n\nThe main questions are:\n\nHow does stimulation affect blood pressure over the year? What is the level of cardiovascular activation throughout the year?\n\nThe study will start during the inpatient stay at the Kessler Institute for Rehabilitation and continue after discharge as an outpatient, totaling about 20-29 sessions over the year.",[28,29,30,31],"Spinal Cord Injuries (SCI)","Orthostatic Hypotension, Dysautonomic","Cardiovascular","Transcutaneous Spinal Stimulation",[33,34,35,36,37,38,39,40,41,42,43,44,45],"Transcutaneous Spinal Cord Stimulation","spinal cord stimulation","orthostatic hypotension","blood pressure","cardiovascular","neuromodulation","acute spinal cord injury","chronic spinal cord injury","inpatient rehabilitation","tilt testing","cold pressor test","ambulatory blood pressure monitoring","autonomic dysfunction following spinal cord injury","RECRUITING","2026-06-26",{"date":49,"type":50},"2026-07-01","ACTUAL",{"date":52,"type":50},"2025-04-01",{"date":54,"type":22},"2026-11",{"name":56,"class":57},"Kessler Foundation","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":58},"100623026","strategy-for-early-recognition-of-cancer-copd--heart-failure-in-the-emergency-department-100623026","NCT07391280","Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department","SEARCH-ED","Inclusion Criteria:\n\nUnconsented Use of Harrison CXR Algorithm in Emergency Department (ED):\n\n* Frontal Chest X-Ray (CXR) (AP or PA) acquired in the Queen Elizabeth University Hospital (QEUH) ED\n* Patients aged 18 or over\n* Appropriate meta data (DICOM) to allow for Harrison CXR processing and secondary capture report provision.\n\nPatient Focus Groups:\n\n* Aged 18 or over\n* Able to provide written, informed consent in English.\n\nClinician Focus Groups:\n\n* Aged 18 or over\n* Able to provide written, informed consent in English.\n* Working as a doctor, advanced nurse practitioner or advanced clinical practitioner in ED, radiology or downstream medical specialties\n* For post-implementation focus groups only, must have at least 4 months experience of working with Harrison CXR algorithm.\n\nDiagnostic Clinic:\n\n* Patients without terminal illness or advanced frailty\n* Usual healthcare provider based in NHS GGC\n\nExclusion Criteria:\n\nApplies to use of unconsented CXRs:\n\n\\- Patient has requested that they are removed from the study, or has objected to the use of AI in their routine clinical care and this has been subsequently upheld by the health board.\n\nApplies to invitation to combined diagnostic clinic:\n\n* Patients not available to follow up, including patients i.e. whose the patient's usual care (or onward care following index admission) is out-with NHS GGC.\n* Patients who have been referred to palliative care for end-stage disease, or patients with severe frailty (i.e. bedbound) will not be invited to the combined diagnostic clinic\n\nFor Patient and Clinician Focus Groups:\n\n* Unable to provide informed written consent in English\n* Aged \\\u003C18",{"count":67,"type":22},17000,[25],"SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital. The aim of the study is to find out if using a computer programme can help doctors diagnose heart and lung problems from chest x-rays.\n\nWe want to compare how many people are diagnosed with heart or lung problems for the first time when doctors have access to the computer programme results, in comparison to when they don't.",[71,30,72],"Cancer","Respiratory",[74,75,76,77,78],"Artificial Intelligence","Chest X-Ray","Lung Cancer","Heart Failure","COPD","2026-05-28",{"date":81,"type":50},"2026-06-01",{"date":83,"type":50},"2026-05-25",{"date":85,"type":22},"2027-06",{"name":87,"class":57},"NHS Greater Glasgow and Clyde",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":99,"conditions":100,"keywords":110,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100630707","phase-1-a-safety-and-tolerability-trial-evaluating-ctx310-in-participants-with-refractory-dyslipidemias-100630707","NCT07491172","A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias","A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias","Key Inclusion Criteria:\n\n1. Age of ≥18 and ≤75 years at the time of signing the informed consent.\n2. Able to provide written informed consent.\n3. Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg\u002FdL - and LDL-C ≥70 mg\u002FdL in participants with ASCVD, or LDL-C ≥70 or 100mg\u002FdL in participants with or without ASCVD respectively, or TG ≥500 mg\u002FdL.\n4. Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening\n5. Female participants must be postmenopausal or surgically sterile.\n6. All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.\n\nExclusion Criteria:\n\n1. Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.\n2. Evidence of liver disease, defined as but not limited to:\n\n   LFTS \\>2 × upper limit of normal (ULN), or total bilirubin \\>2 × ULN, or INR \\>1.5 × ULN, or liver stiffness measured by liver elastography\n3. Abnormal or compromised function of kidney, heart, blood or liver.\n4. Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.\n5. Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).\n6. Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.\n7. Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).\n8. Women of childbearing potential.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.\n\nNote: The inclusion and exclusion criteria listed represent the global protocol. Additional or modified eligibility criteria may apply in certain countries in accordance with local regulatory and ethics committee requirements and the approved country-specific protocol.",{"count":96,"type":22},90,[98],"PHASE1","This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.",[30,101,102,103,104,105,106,107,108,109],"Metabolic Disease","Dyslipidemias","Lipid Disorder","Hypertriglyceridemia","Heterozygous Familial Hypercholesterolemia (HeFH)","Homozygous Familial Hypercholesterolemia (HoFH)","Severe Hypertriglyceridemia (sHTG)","Mixed Hyperlipemia","Hypercholesterolaemia",[111],"Refractory Dyslipidemias","2026-05-19",{"date":114,"type":50},"2026-05-22",{"date":116,"type":50},"2024-06-21",{"date":118,"type":22},"2028-06",{"name":120,"class":121},"CRISPR Therapeutics AG","INDUSTRY",18,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100598123","improving-the-heart-health-of-home-health-aides-100598123","NCT07067398","Improving the Heart Health of Home Health Aides","Improving the Cardiovascular Health of Home Health Aides","VITAL","Inclusion Criteria:\n\n* Currently working as a home health aide\n* Speak English or Spanish\n* ≥ 18 years of age\n* Have low CV Health as assessed by LE8 components made up by physical health measurements (blood pressure, BMI) and general self-reported health (physical activity, diet, smoking, sleep); calculated to be a score of 0-50 (the total score ranges from 0-100)\n\nExclusion Criteria:\n\n* Less than 1 year of job experience as a home health aide\n* Does not possess a smartphone\n* Gotten dizzy before with a finger stick blood sugar\u002Fcholesterol test\n* Have a history of syncope with a finger stick blood sugar\u002Fcholesterol test",{"count":132,"type":22},40,[25],"The goal of this early-stage study is to support the heart health of home health aides, a workforce that provides care for adults at home but whose own health has been historically poor. To do this, the study will use Life's Essential 8 (LE8), a program developed by the American Heart Association (AHA) that promotes cardiovascular wellness through education and lifestyle changes. The program has been adapted specifically for home health aides and will be delivered by trained \"peer coaches,\" who are fellow home health aides who will help guide participants through the program.\n\nThe main questions the study aims to answer are:\n\n* Will the LE8 intervention, which provides cardiovascular health education and support with positive thinking, be used by home health aides and do they like it?\n* Does the LE8 intervention actually improve home health aides' cardiovascular health after the intervention's conclusion compared to baseline?\n\nParticipants will be paired with a trained peer coach and take part in the 10-week program over the course of 6 months. The program includes support for healthy behaviors and positive thinking, with the goal of making lasting improvements in cardiovascular health.",[30,136,137,138],"Cardiovascular (CV) Risk","Cardiovascular Disease (CVD) Risk Factors","Cardiovascular Health",[140,141,142],"cardiovascular health intervention","home health aide","peer coaching",{"date":114,"type":50},{"date":145,"type":50},"2025-09-09",{"date":147,"type":22},"2026-09",{"name":149,"class":57},"Weill Medical College of Cornell University",2,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":163,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":58},"100639542","whole-life-investigation-of-lishui-longevity-100639542","NCT07592962","Whole-life Investigation of Lishui Longevity","Whole-life Investigation of Lishui Longevity Cohort Study","WILL","Inclusion Criteria:\n\n* Aged 30 to 80 years old; male-to-female ratio of 1:1; permanent residents in Lishui City; physically healthy; voluntary participation in the project with signed informed consent.\n\nExclusion Criteria:\n\n* Individuals ever diagnosed with malignant tumors or cardiovascular and cerebrovascular diseases by physicians or other health professionals; those with unstable vital signs or an expected survival time of less than 3 months; participants with incomplete basic information, and those unable to cooperate with subsequent follow-up.","30 Years","80 Years",{"count":162,"type":22},4500,"10 Years","OBSERVATIONAL","1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors.\n2. To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.",[167,168,30],"Ischemic Stroke","Chronic Disease",[170,171,172],"acute ischemic stroke","carotid artery stenosis","Hepatic fibrosis","2026-05-12",{"date":175,"type":50},"2026-05-18",{"date":175,"type":22},{"date":178,"type":22},"2036-05-31",{"name":180,"class":57},"The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":16,"sex":187,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":58},"100591029","phase-2-focusing-on-the-menopausal-transition-to-improve-mid-life-womens-health-100591029","NCT06975111","Focusing on the Menopausal Transition to Improve Mid-Life Women's Health","Inclusion Criteria:\n\n* aged 45-55\n* In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18\n* No current use of hormone therapy or hormonal contraception\n* Presence of a uterus and at least one ovary in order to track menstrual patterns\n* Have a smartphone and broadband access adequate to accept telehealth appointments\n\nExclusion Criteria:\n\n* Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)\n* Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.\n* Pregnancy or actively trying to get pregnant\n* Inability to adhere to study protocol schedule\n* Untreated alcoholism\n* Un- Diagnosed abnormal uterine bleeding\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\\> 30 kg\u002Fm2.","FEMALE","45 Years","55 Years",{"count":191,"type":22},200,[193,194],"PHASE2","PHASE3","What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",[197,198,199,30],"Menopause","Menopause Hot Flashes","Menopause Related Conditions","2026-04-24",{"date":202,"type":50},"2026-04-30",{"date":204,"type":50},"2026-03-01",{"date":206,"type":22},"2030-10-01",{"name":208,"class":57},"University of Colorado, Denver",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100482971","collection-of-blood-samples-for-new-diagnostic-devices-2-100482971","NCT05568966","Collection of Blood Samples for New Diagnostic Devices 2","Collection of Venous and Capillary Blood Samples for the Research, Optimisation and Calibration of New Diagnostic Devices 2","NOVEL-2","Inclusion Criteria\n\n* Subject 18 years of age.\n* Willing and able to provide written informed consent and comply with study procedures.\n* Patients attending a definitive care team with research capabilities which has been enroled in this collection study.\n* Patients who can read and understand written English.\n* The subject must present as one of the following cohorts:\n\n  1. Group A - Embolism Cohort - Patients presenting with symptoms indicative of thromboembolic events.\n  2. Group B - Infection or Inflammation Cohort - Patients presenting with symptoms indicative of infection or inflammatory disorders.\n  3. Group C - Cardiovascular Cohort - Patients presenting with symptoms indicative of heart failure or acute coronary syndrome.\n  4. Group D - Renal Cohort - Patients presenting with symptoms indicative of renal disorders.\n  5. Group E - Other Cohort. - Patients who are not eligible for any of the above groups.\n\nExclusion Criteria\n\n* Subject \\\u003C18 years of age.\n* Vulnerable populations deemed inappropriate for the study by the sites Principal Investigator.\n* Patients who have previously been enroled in any LumiraDx NOVEL study in the past 3 months and re-entry would breach the 24mL and or 6 fingersitck maximums.",{"count":218,"type":22},20000,[25],"To research and develop new state of the art diagnostic biomarkers on the LumiraDx Platform that are comparable to the approved gold standard reference methods and will radically enhance clinicians and patients ability to monitor health conditions and improve outcomes by delivering the results near patient at the point of care.",[222,30,223,224,225],"Embolism and Thrombosis","Renal","Inflammation","Infections","2026-04-17",{"date":228,"type":50},"2026-04-22",{"date":230,"type":50},"2022-07-11",{"date":232,"type":22},"2026-08-20",{"name":234,"class":121},"LumiraDx UK Limited",7,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":58},"100623455","the-role-of-edhfs-on-blood-pressure-following-a-bout-of-prolonged-sitting-100623455","NCT07396857","The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting","The Role of Endothelial-Derived Hyperpolarization Factors on 24-hr Blood Pressure Regulation Following a Bout of Prolonged Sitting","Inclusion Criteria:\n\n* Are between the ages of 18-65.\n* Have a body mass index of \\\u003C40kg\u002Fm2 (non-obese).\n* Have not smoked nicotine or marijuana-containing products most days of the week within the past 6 months.\n* Have not been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease.\n* Are normotensive.\n* Are not currently taking any medications for cardiovascular, metabolic, pulmonary, or neurological disorders, or taking sildenafil regularly.\n* Are not allergic to the adhesive used to secure the activPAL activity monitors.\n* Are not pregnant or breastfeeding.\n* Are not regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements.\n\nExclusion Criteria:\n\n* o Younger than 18 years old. Individuals younger than 18 demonstrate more variable peak FMD responses and require multiple assessments to determine peak response.\n\n  * Over the age of 65. There are age-related impacts on arterial function and the responses to sitting.\n  * Body mass index of \\>40 kg\u002Fm2 (i.e., obese II category)(6-8).\n  * Smoked nicotine or marijuana-containing products most days of the week within the past 6 months. Cardiovascular health for participants who smoke is poor compared to those who do not smoke, which will negatively impact our arterial function outcomes.\n  * Have been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease. Such conditions impact our assessments of arterial health. The results of unhealthy participants are not of interest in this study.\n  * Hypertension (seated resting systolic pressure \\>139 mmHg and\u002For diastolic pressure \\>89 mmHg). Hypertensive individuals have impairments in artery health, which will affect their baseline artery health measures.\n  * Hypotensive (seated resting systolic pressure \\\u003C90 mmHg and\u002For diastolic pressure \\\u003C60 mmHg). Hypotensive people are more likely to experience further reductions in blood pressure during the sitting protocol, which will increase the risk of fainting and\u002For dizziness.\n  * Have a history of fainting and\u002For dizziness during sitting or standing.\n  * Prescribed medications for cardiovascular, metabolic, pulmonary, or neurological disorders. This includes people using hormone replacement therapy. These medications will interfere with our assessments and interpretation of arterial health.\n  * Have a known allergy to the clear medical adhesive used to secure the activPAL activity monitors.\n  * Females who are pregnant or breastfeeding. Pregnant and breastfeeding females are ineligible to participate. This is due to the known increases in arterial vasodilation associated with pregnancy related sex hormones.\n  * Currently or recently (within the past 6 months) regularly taking sildenafil or other medications that increase the relaxing effects of nitric oxide in arteries. Such medication will influence artery blood flow and flow-mediated dilation responses.\n  * Are regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements. These are to minimize the chance of a participant experiencing an adverse reaction to the fluconazole tablet.","65 Years",{"count":132,"type":22},[25],"Canadians spend most of their day in sedentary postures (i.e., sitting, lying, reclining). While the beneficial impacts of physical activity on the heart are well-established, less is known about the consequences during time spent in sedentary postures. Currently, we know that spending time in a bout of uninterrupted sitting disrupts blood pressure regulation. However, it is unknown if there are any 'carry over' effects following uninterrupted sitting bouts (i.e., over the next 24-hours). The release of chemicals from arteries controls how stiff or relaxed they are and is important for controlling blood pressure. This is especially true for arteries directly impacted by sitting (e.g., the popliteal artery behind the knee) and that send blood to the brain (e.g., the carotid artery). We have also established that endothelial-derived hyperpolarizing factors (EDHF, chemicals that relax the artery) are important for the relaxation of the artery the popliteal artery. However, we do not know if the effects of EDHFs on this artery are decreased during or after a bout of uninterrupted sitting. A bout of prolonged sitting also causes blood pressure and fluctuations in blood pressure to increase. Importantly, we reported that fluctuations in blood pressure caused by sitting are higher in young males versus females, but average blood pressure was higher among females. These findings suggest that sitting exerts sex differences in the control of blood pressure. Importantly, these effects were only demonstrated during the 2-hour bout of sitting. As such, it is unknown whether blood pressure is negatively impacted after prolonged sitting. The proposed study will determine the impact of EDHFs on blood pressure regulation following a 2-hour bout of prolonged sitting among a group of healthy males and females. Continuous heart rate (via electrocardiogram) and blood pressure (via finger cuff), as well as blood flow from the common carotid artery (in the neck), middle cerebral artery (in the brain) and popliteal artery (behind the knee) will be measured before and after sitting (via ultrasound). The ability of the popliteal artery to relax will be assessed using ultrasound following the release of a pressure cuff. Finally, 24-hour blood pressure and heart rate will be recorded after sitting using a monitor worn for 24-hours. The role of EDHFs will be investigated by comparing 1) baseline blood flow and blood pressure responses (no sitting), 2) blood pressure responses following a 2-hour bout of sitting, and 3) the blood pressure responses following a 2-hour bout of sitting while suppressing the release of EDHFs (via fluconazole ingestion).",[30],[249,250,251,252],"Arterial function","Sedentary time","Sex differences","Vasoactive substances","2026-04-07",{"date":255,"type":50},"2026-04-13",{"date":257,"type":50},"2025-11-01",{"date":259,"type":22},"2026-12-15",{"name":261,"class":57},"Université de Sherbrooke",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":274,"conditions":275,"keywords":281,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100580704","phase-4-effects-of-donor-recipient-sex-matched-blood-transfusion-on-patient-outcomes-100580704","NCT06840756","Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes","Effects of Donor-recipient Sex-matched Versus Sex-mismatched Red Blood Cell Transfusion on Outcomes in Critically Ill Adult Patients","SexMATTERS RCT","Inclusion Criteria:\n\n* Adults (age ≥18);\n* Admission to a participating ICU;\n* Requiring RBC transfusion.\n\nExclusion Criteria:\n\n* Requirement for a specialized RBC product or unit not readily available in inventory (e.g., rare blood type, washed RBCs, complex RBC antibodies, etc.);\n* Massively bleeding patient (i.e., ≥4 units of blood ordered at one time, or Massive Hemorrhage Protocol initiated, or an urgent blood request made);\n* Sex unknown or sex other than male or female (i.e. intersex);\n* Do not have a valid Ontario Health Insurance Plan (OHIP) health card number.",{"count":271,"type":22},11082,[273],"PHASE4","Red blood cell (RBC) transfusions are selected based upon matching donor and recipient blood group: donor and recipient sex are not considered when selecting blood for transfusion. Hence, transfused patients can currently receive sex-matched and\u002For unmatched RBCs when transfusions are given. Sex-matched stem cell transplants, and some solid organ transplants, have shown that sex-matching donor to recipient improves patient outcomes. Recent exploratory studies have also suggested that patient outcomes could be improved by sex-matching for RBC transfusion. There is emerging evidence of underlying biologic mechanism(s) to support these observations. This study is designed as a randomized controlled trial and will explore the impact on patients who receive RBC transfusions from donors of the same sex (\"sex-matched\") compared with donors of the opposite sex (\"sex-mismatched\").\n\nThe trial will study adult patients admitted to the Intensive Care Unit who require an RBC transfusion. Patients will be assigned (through a process called randomization) to receive sex-matched RBCs or sex-mismatched RBCs to determine if there is a difference in mortality between those receiving matched versus mismatched RBCs. The results of this trial could have direct implications on resources, blood inventory, and RBC transfusion ordering practices.",[276,277,278,279,280,30],"Red Blood Cell Transfusions","Sex Differences","Health Services","Critically Ill Intensive Care Unit Patients","Hematology",[282,283,284,285,286,287,37,288,289,290,291],"transfusions","red blood cell transfusions","sex-matched","sex-mismatched","intensive care unit","ICU","circulatory","hematology","mortality","blood donor characteristics","2026-03-10",{"date":294,"type":50},"2026-03-12",{"date":296,"type":50},"2025-09-11",{"date":298,"type":22},"2029-03-31",{"name":300,"class":57},"Michelle Zeller",8,{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":150},"100609721","ai-platform-for-fatigue-and-depression-detection-100609721","NCT07218263","AI Platform for Fatigue and Depression Detection","Efficacy of a Novel Web-based Fatigue and Cognitive Assessment Platform in Detecting Fatigue and Depression","Inclusion Criteria:\n\n* Age ≥18, English-speaking, able to consent\n\nExclusion Criteria:\n\n* Active substance use, nonverbal, cognitive disability, active suicidal\u002Fhomicidal ideation","99 Years",{"count":311,"type":22},100,"This observational study evaluates the accuracy of the Okaya AI platform in detecting fatigue and depression in cardiology patients, comparing its assessments to PHQ-9 and Fatigue Assessment Scale scores.",[314,315,30],"Depression Disorders","Fatigue Symptom",[317,318,74],"Fatigue","Depression","2026-02-23",{"date":321,"type":50},"2026-02-25",{"date":323,"type":50},"2025-12-01",{"date":325,"type":22},"2026-05",{"name":327,"class":57},"Brijesh Patel",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":58},"100622371","decoupling-immunotherapy-toxicity-and-cancer-response-100622371","NCT07382752","Decoupling Immunotherapy Toxicity and Cancer Response","Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Plan to start immune checkpoint inhibitor for cancer therapy\n\nExclusion Criteria:\n\n1. No baseline blood collection prior to initiation\n2. At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator",{"count":336,"type":22},1200,"This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.",[339,30],"Tumor","2026-01-26",{"date":342,"type":50},"2026-02-03",{"date":344,"type":50},"2026-01-09",{"date":346,"type":22},"2030-06-30",{"name":348,"class":57},"M.D. Anderson Cancer Center",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":16,"sex":17,"minAge":356,"maxAge":243,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":365,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":150},"100606711","adequate-hydration-and-health-outcomes-100606711","NCT07179107","Adequate Hydration and Health Outcomes","HYDRATE","Inclusion Criteria:\n\n* BMI 18.5-24.9 or 30.0-39.9 kg\u002Fm2\n* HbA1c ≤7%\n* Age 20-65 y\n* available for 8 consecutive weeks same day and time\n\nExclusion Criteria:\n\n* Diabetes\n* HbA1c \\>7% BMI ≤18.5, BMI of 25 to \\\u003C30, or ≥ 40 kg\u002Fm2\n* night shifting work\n* losing or gaining weight during the last 2 months (\\>5 lbs. fluctuation)\n* thyroid medication\n* bariatric surgery\n* Habitual strenuous exercise (\\>120 min\u002Fweek) Strenuous exercise is defined as activities that take hard physical effort and make you breathe much harder than normal.\n* Construction and other workers that spend signifant portion of their work day outdoors\n* Commuting by bicycle\n* Eating disorders\n* Use of aspirin during the duration of the study\n* Cancer\n* Renal disease (including kidney stones or recurrent urinary track infections\n* Hepatic disease\n* Cardiac conditions\n* Current infection requiring medication\n* Chronic, contagious, infectious diseases such as tuberculosis, Hepatitis A, B, C, or HIV\n* Medication that could affect appetite or body weight regulation\n* GLP1-RA medication\n* Anti-depressent SSRI medication\n* Testosterone replacement therapy\n* Participating in another study at the same time\n* Unable to abstain from alcohol during the study\n* Unable to limit caffeinated beverage intake to 1 cup per day\n* Donated blood during the past two months\n* Uneasibly acessable veins\n* Does not have smart phone","20 Years",{"count":358,"type":22},144,[25],"Cardiovascular diseases (CVD) are the leading cause of death in middle- and high-income countries, according to data from the World Health Organization (WHO). Epidemiological studies have associated low water intake and underhydration with diabetes, chronic kidney disease, and an increased risk of CVD. Similarly, the prevalence of chronic metabolic dysfunction is increasing dramatically worldwide, becoming both a significant public health concern and a global economic burden. Reports from the WHO indicate that the number of people with diabetes worldwide has risen from 108 million in 1980 to 422 million in 2014, representing 8.5% of adults. Therefore, there is an urgent need to identify modifiable risk factors that could help prevent metabolic dysfunction and mitigate the epidemic of type 2 diabetes (T2D). Evidence suggests that the hormone arginine vasopressin (AVP) may play a key role. AVP is the primary hormone responsible for regulating body fluid balance; however, increased AVP secretion, such as under conditions of low water intake, appears to be a risk factor for developing diabetes.\n\nIncreasing water intake may represent a simple and cost-effective way to improve glucose regulation and cardiovascular health. However, many individuals do not prefer drinking plain water, and although beverages with high sugar content may promote greater fluid intake, they also contribute additional calories that can negatively impact body weight and overall health. Thus, the central research question of this study is whether improving hydration with non-sugar-sweetened beverages can provide equivalent benefits for hydration and health outcomes in adults.\n\nAim 1: To explore the association between habitual fluid intake and fluid preferences (water and non-sugar-sweetened beverages), hydration biomarkers, and health outcomes in normal-weight and obese adults.\n\nAim 2: To compare the impact of increased total water intake, provided as plain water or non-sugar-sweetened beverages, on hydration, cardiovascular health, and glucose regulation in normal-weight and obese adults.",[362,363,364,30],"Dehydration","Dehydration (Physiology)","Glucose Abnormalities",[366,367,368,369,370],"hydration","dehydration","underhydration","fluid intake","non caloric sweeteners",{"date":372,"type":50},"2026-01-27",{"date":374,"type":50},"2025-09-29",{"date":376,"type":22},"2028-12-31",{"name":378,"class":57},"Arizona State University",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":386,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":394,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":401,"locationsCount":4},"100620684","investigation-of-autonomic-stress-response-patterns-in-college-students-with-varying-physical-activity-levels-100620684","NCT07360821","Investigation of Autonomic Stress Response Patterns in College Students With Varying Physical Activity Levels","ANS Stress\u002FPA","Inclusion Criteria:\n\nHealthy young adults aged 18-25 years\n\nBody Mass Index (BMI) within the range of 18.5-23.9 kg\u002Fm 2\n\nNo history of systematic professional athletic training (for sedentary group) or confirmed training background (for athlete groups)\n\nNo exercise contraindications or history of cardiovascular, respiratory, or metabolic diseases\n\nNo family history of sudden cardiac death\n\nAbility to understand the study protocol and sign the informed consent form\n\nExclusion Criteria:\n\nHistory of limb sports injury within the past 6 months or unhealed fractures\n\nHabits of smoking or chronic alcohol consumption\n\nPresence of implanted electronic devices (e.g., pacemakers)\n\nClinical diagnosis of psychiatric disorders such as anxiety or depression\n\nRecent use of medications affecting autonomic or cardiovascular function\n\nRegular practice of meditation or ongoing psychotherapy\n\nIrregular menstrual cycles (for female participants)\n\nPeripheral neuropathy or other autonomic nervous system disorders",{"count":387,"type":22},60,"This study aims to investigate the differences in cardiovascular stress response patterns among individuals with various physical activity levels (sedentary controls and different types of athletes). By synchronously monitoring ECG, heart rate, skin sympathetic nerve activity (SKNA), blood pressure, and cardiac output, the study will characterize physiological dynamics during resting, orthostatic challenge, cold pressor stress, and maximal exercise.",[390,30,391],"Autonomic Nervous System Activity","Physical Activity Level",[393],"SKNA; HRV; Blood Pressure Variability; Athletes; Cardiopulmonary Exercise Testing","NOT_YET_RECRUITING","2026-01-17",{"date":397,"type":50},"2026-01-22",{"date":321,"type":22},{"date":400,"type":22},"2026-07-30",{"name":402,"class":57},"Beijing Sport University",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":418,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":435},"100617598","breathlessness-diagnostics-in-a-box-biab-for-primary-care-a-multi-country-quality-improvement-project-using-a-randomized-stepped-wedge-design-100617598","NCT07320703","\"Breathlessness Diagnostics in a Box\" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design","BiaB","The study aims to capture the real-world heterogeneity in primary care practices and patients. Therefore, inclusion and exclusion criteria are limited.\n\nInclusion criteria\n\n* Patient must be at least 18 years old at the time of signing the informed consent.\n* Patients that present with undiagnosed dyspnea (breathlessness); or Patients who have existing diseases that could cause breathlessness, but have residual or increasing breathlessness that could be caused by other not yet detected diseases. Or HCP has doubts or requires additional tests to confirm diagnosis or to suspect new, parallel, diagnoses. For example, breathlessness in patients assessed within the framework of Cardiovascular Risk Management or for COPD monitoring\n\nExclusion criteria\n\n1. Acute worsening of previous diagnosed chronic disease where there is no suspicion of comorbidities (for example when a patient with clear COPD diagnosis has an exacerbation where typically the HCP will not perform additional tests).\n2. Inability to understand and sign the written consent form.",{"count":411,"type":22},900,[25],"This prospective stepped-wedge study evaluates whether use of the Breathlessness diagnostics in a Box (BiaB) tool shortens the time to diagnosis in patients presenting with breathlessness, compared with usual care. The study is conducted in general practice settings in the Netherlands, Spain, and Portugal. Participating sites start with a usual care period and transition sequentially to the BiaB intervention period. Data are collected during routine clinical visits, from electronic medical records, and through questionnaires completed by patients and healthcare professionals.",[415,30,416,417],"Breathlessness","Pulmonary","Mental Disease",[419,420,421,422,423,424],"breathlessness","diagnostics","cardiovascular disease","pulmonary disease","mental disease","cardiopulmonary risk","2026-01-06",{"date":427,"type":50},"2026-01-07",{"date":429,"type":50},"2024-08-05",{"date":431,"type":22},"2027-04",{"name":433,"class":434},"General Practitioners Research Institute","NETWORK",3,{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":11,"sex":187,"minAge":18,"maxAge":243,"enrollmentInfo":443,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":394,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":463,"leadSponsor":465,"locationsCount":4},"100613266","cardiometabolic-and-hormonal-adaptations-to-4-month-zumba-training-in-overweightobese-women-100613266","NCT07264348","Cardiometabolic and Hormonal Adaptations to 4-Month Zumba Training in Overweight\u002FObese Women","Effects of a 4-month Intervention on Cardiometabolic, Hormonal, Inflammatory, Liver, Renal, Electrolyte, and Muscle Enzyme Parameters in Pre- and Post-Menopausal Overweight and Obese Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female, aged 18-65 years\n* BMI ≥ 25 kg\u002Fm²\n* Pre-menopausal or post-menopausal (classified clinically)\n* Voluntary written informed consent\n\nExclusion Criteria:\n\n* Hormonal therapy or weight-loss medications\n* Endocrine diseases or chronic illness\n* Recent intense physical training (\\\u003C48 hours before baseline)",{"count":444,"type":22},73,[25],"This study aims to evaluate the effects of a 4 month Zumba training program on cardiometabolic, hormonal, inflammatory, hepatic, renal, and functional parameters in overweight and obese women. Participants will be classified according to menopausal status (pre- or post-menopausal) and randomly assigned to an exercise group or a non-exercise control group.",[448,30,449],"Hormone","Obesity & Overweight",[451,452,453,454,455,456,457,458],"Overweight","Obesity","Pre-menopause","Post-menopause","Zumba Training","Cardiometabolic Health","Hormonal Adaptations","Lipid Profile","2025-11-24",{"date":461,"type":50},"2025-12-04",{"date":323,"type":22},{"date":464,"type":22},"2026-04-15",{"name":466,"class":57},"High Institute of Sports and Physical Education of Kef",{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":17,"minAge":474,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":394,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":4},"100611348","phase-3-bempedoic-acid-versus-statins-in-primary-prevention-patients-with-suboptimal-statin-adherence-effects-on-ldl-c-reduction-and-tolerability-100611348","NCT07239414","Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability","BASIS","Inclusion Criteria\n\n* Adults aged ≥40 years with no established ASCVD (no prior myocardial infarction, stroke, or acute coronary syndrome).\n* Indicated for lipid-lowering therapy (LDL-C ≥130 mg\u002FdL or 10-year ASCVD risk\n\n  ≥7.5%).\n* Documented history of poor statin adherence, defined as:\n\n  * Self-reported adherence \\\u003C80% in the past 3 months, or\n  * Prior statin discontinuation for adverse effects documented in the medical record.\n* Willingness to provide written informed consent. Exclusion Criteria\n* Established ASCVD (secondary prevention).\n* Severe hepatic impairment (ALT or AST \\>3× upper limit of normal).\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Pregnancy, breastfeeding, or women of childbearing potential not using contraception.\n* Current or planned treatment with PCSK9 inhibitors, fibrates, or niacin.\n* Known hypersensitivity to study drugs or excipients.","40 Years",{"count":476,"type":22},690,[194],"Bempedoic acid is an oral, non-statin LDL-cholesterol (LDL-C) lowering agent that inhibits ATP citrate lyase (ACL), upstream of HMG-CoA reductase (the enzyme inhibited by statins).\n\nMDPI\n\n+1\n\nIn patients with hypercholesterolemia who are unable to tolerate statins, or have sub-optimal statin adherence\u002Ftolerance, bempedoic acid has been shown to reduce LDL-C by \\~20-30% (monotherapy) and more when added to other therapies (e.g., ezetimibe) (≈30-40%).\n\nPubMed\n\n* 2 medicinejournal.in\n* 2\n\nIn the large primary-prevention subgroup of the trial CLEAR Outcomes (statin-intolerant patients without prior cardiovascular event), bempedoic acid (180 mg daily) lowered LDL-C by \\~21.3% and hs-CRP by \\~21.5%. It also was associated with a significant reduction in major adverse cardiovascular events (MACE): hazard ratio 0.70 (95% CI 0.55-0.89) versus placebo over \\~40 months.\n\nPubMed +1\n\nRegarding tolerability: muscle-related adverse events appear lower compared to statins (because bempedoic acid is activated only in the liver, not in skeletal muscle) and it appears generally well tolerated, but there are signals of increased uric acid\u002Fgout, elevated hepatic enzymes, and creatinine\u002Frenal effects.\n\nMDPI\n\n+1\n\nComparative cardiovascular benefit (when normalized per unit LDL-C reduction) suggests that bempedoic acid may yield similar relative risk reductions as statins, though absolute LDL-C lowering is less.",[30],[481],"bempodoic acid","2025-11-16",{"date":484,"type":50},"2025-11-20",{"date":486,"type":22},"2025-11-10",{"date":488,"type":22},"2027-02-21",{"name":490,"class":57},"Sohaib Ashraf",{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":16,"sex":17,"minAge":497,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":58},"100498840","exercise-to-slow-cardiovascular-ageing-progression-100498840","NCT05775484","Exercise to Slow Cardiovascular Ageing Progression","Inclusion Criteria:\n\n* Age \\>=21 years old\n* Outdoor ambulant\n\nExclusion Criteria:\n\n* Wheelchair or bed-bound\n* Dementia\n* Residing in sheltered or nursing home\n* Cancer\n* Participation in ongoing clinical trials that involve interventional drugs or devices\n* Aneurysms\n* Acute infections (in the last six months)\n* Uncontrolled thyrotoxicosis\n* Neuromuscular, musculoskeletal or rheumatoid disorders that are exacerbated by exercise\n* Uncontrolled asthma or chronic lung disease\n* Restrictive lung disease","21 Years","100 Years",{"count":500,"type":22},450,"In ageing, deleterious alterations in cardiovascular (CV) structure and function increase risks of ageing-related cardiovascular disease (CVD). Investigators found that these CV alterations were associated with circulating serum metabolites, suggesting a metabolic basis to CV ageing. Investigators hypothesize that modification of these metabolites by intervention, such as exercise, may retard CV alterations and reduce CVD in ageing.",[503,504,30],"Cardiac Ageing","Exercise","2025-06-03",{"date":507,"type":50},"2025-06-05",{"date":509,"type":50},"2023-05-01",{"date":511,"type":22},"2050-12-31",{"name":513,"class":57},"National Heart Centre Singapore",{"id":515,"slug":516,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":309,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":58},"100572283","virtual-ward-assisted-very-early-discharge-of-low-risk-stemi-patients-the-valiant-stemi-trial-100572283","NCT06731257","Virtual Ward-Assisted Very earLy dIschArge of Low-rIsk STEMI patieNTs: the VALIANT-STEMI Trial","VALIANT-STEMI","Inclusion Criteria:\n\n* Successful revascularisation following STEMI\n* Zwolle score \\\u003C=3\n* No bystander disease awaiting inpatient intervention at the time of screening or consent (so if they have had intervention to a bystander vessel before this they would be eligible)\n\nExclusion Criteria:\n\n* Haemodynamic instability (Killip class \\>I)\n* Left ventricular ejection fraction \\\u003C45%\\\u003C40%\n* Sustained ventricular or atrial arrhythmias requiring intervention\n* No support at home or social or physical circumstances preventing early discharge\n* Unable to use home monitoring equipment\n* Unwilling to consent or follow instructions\n* Patients visiting from out of our catchment area\n* Out-of hospital cardiac arrest\n* Patients repatriated to their local hospital within 24 hours\n* New or worsening renal failure (i.e. creatinine \\>=1.5x baseline)",{"count":522,"type":22},600,[25],"Observational studies have suggested that early discharge (24hrs with follow up virtually by telephone) of patients who are low risk and have had successful treatment following ST elevation myocardial infarction is safe. This has not been tested in a randomised controlled trial. In this trial the study team propose to identify low risk patients and randomise them to usual care or early discharge and follow up virtually by telephone. The primary endpoint would be readmission to hospital or all cause death up to 30 day following the event. If the outcome is positive, the study will assist early discharge of patients, reduce length of stay, potentially improve patient well being and have positive financial implications for the health service",[30],"2024-12-11",{"date":528,"type":50},"2024-12-12",{"date":530,"type":50},"2024-06-24",{"date":532,"type":22},"2026-03",{"name":534,"class":57},"The Leeds Teaching Hospitals NHS Trust",{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":544,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":58},"100565778","a-preventive-multidisciplinary-primary-care-intervention-organized-around-a-therapeutic-garden-acceptability-to-patients-suffering-from-cardio-neurovascular-pathology-and-to-those-involved-in-the-action-100565778","NCT06646601","A Preventive, Multidisciplinary Primary Care Intervention Organized Around a Therapeutic Garden: Acceptability to Patients Suffering from Cardio-neurovascular Pathology and to Those Involved in the Action.","ArTERRE","Inclusion Criteria:\n\n* age \\> 18 years old;\n* living in the vicinity (+-20 km) of Gap, Laragne-Montéglin, Veynes and Clermont-Ferrand;\n* having been invited to take part in the intervention by the caregivers of the medical structures\n* suffering from an ALD based on CNAM medical criteria (stroke, AOMI, rhythm disorders, valvular heart disease, congenital heart disease, stage I and II heart failure), severe hypertension, chronic coronary disease)\n\nExclusion Criteria:\n\n* heart failure based on CNAM medical criteria (ALD n°5) stage III and IV according to NYHA classification ;\n* with a contraindication to physical activity ;\n* living in an institution;\n* unable to walk more than 100 m independently;\n* Alzheimer's disease or other dementias based on CNAM medical criteria ;\n* with an unlabelled cognitive impairment limiting comprehension.",{"count":543,"type":22},157,[25],"A preventive, multidisciplinary primary care intervention organized around a therapeutic garden: Acceptability to patients suffering from cardio-neurovascular pathology and to those involved in the action.",[547,30,548,549,550,551,552],"Vascular Disease","Atrial Fibrillation (AF)","Heart Failure NYHA Class II","Cardiomyopathies","Stroke, Ischemic","Hypertension Resistant to Conventional Therapy","2024-10-15",{"date":555,"type":50},"2024-10-17",{"date":557,"type":50},"2024-04-09",{"date":559,"type":22},"2026-10",{"name":561,"class":57},"Assistance Publique Hopitaux De Marseille"]